LLY vs PFE
By Alex · Tickerpine
Eli Lilly and Company vs Pfizer, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | PFE |
|---|---|---|
| Price | $1,220.28 | $26.31 |
| Market cap | $1.09T | $149.96B |
| P/E ratio | 41.0 | 35.1 |
| ROE | 102.29% | 5.01% |
| Profit margin | 33.53% | 6.80% |
| Revenue growth | 47.70% | 2.60% |
| Dividend yield | 0.57% | 6.46% |
| Beta | 0.51 | 0.28 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs PFE in plain English
- LLY is the bigger company — about 7.3× the market cap of PFE.
- PFE is cheaper on earnings (P/E 35.1 vs 41.0).
- LLY earns a higher return on equity (102% vs 5%).
- LLY is growing revenue faster (48% vs 3%).
- PFE has the higher dividend yield (6.46% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
PFE return calculator
See what $1,000 in Pfizer, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.